Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Wolstenholme

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Health Policy (Amsterdam, Netherlands)|July 16, 2008
From cost-effectiveness information to decision-making on liquid-based cytology: Mind the gapRosa Legood, Jane Wolstenholme, Alastair Gray
International Journal of Urology : Official Journal of the Japanese Urological Association|April 17, 2014
Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policiesJose Leal, Freddie Hamdy, Jane Wolstenholme
Cost Effectiveness and Resource Allocation : C/E|April 29, 2010
Burden of disease and costs of aneurysmal subarachnoid haemorrhage (aSAH) in the United KingdomOliver Rivero-Arias, Alastair Gray, Jane Wolstenholme
BMJ (Clinical Research Ed.)|January 10, 2006
Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studiesRosa Legood, Alastair Gray, Jane Wolstenholme, et al.
Health Economics|April 30, 2003
Missing... presumed at random: cost-analysis of incomplete dataAndrew Briggs, Taane Clark, Jane Wolstenholme, et al.
BMC Health Services Research|July 17, 2019
Estimating the cost-effectiveness of salt reformulation and increasing access to leisure centres in England, with PRIMEtime CE model validation using the AdViSHE toolAdam D M Briggs, Jane Wolstenholme, Peter Scarborough
Plos One|May 26, 2018
Estimating comparable English healthcare costs for multiple diseases and unrelated future costs for use in health and public health economic modellingAdam D M Briggs, Peter Scarborough, Jane Wolstenholme
BMJ Open|June 22, 2022
Estimating BMI distributions by age and sex for local authorities in England: a small area estimation studyBen Amies-Cull, Jane Wolstenholme, Linda Cobiac, et al.
Population Health Metrics|May 7, 2016
Choosing an epidemiological model structure for the economic evaluation of non-communicable disease public health interventionsAdam D M Briggs, Jane Wolstenholme, Tony Blakely, et al.
Health Services Management Research|November 1, 2017
Translational health economics: The key to accountable adoption of in vitro diagnostic technologiesChristopher P Price, Jane Wolstenholme, Patrick McGinley, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Health Policy (Amsterdam, Netherlands)|July 16, 2008
From cost-effectiveness information to decision-making on liquid-based cytology: Mind the gapRosa Legood, Jane Wolstenholme, Alastair Gray
International Journal of Urology : Official Journal of the Japanese Urological Association|April 17, 2014
Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policiesJose Leal, Freddie Hamdy, Jane Wolstenholme
Cost Effectiveness and Resource Allocation : C/E|April 29, 2010
Burden of disease and costs of aneurysmal subarachnoid haemorrhage (aSAH) in the United KingdomOliver Rivero-Arias, Alastair Gray, Jane Wolstenholme
BMJ (Clinical Research Ed.)|January 10, 2006
Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studiesRosa Legood, Alastair Gray, Jane Wolstenholme, et al.
Health Economics|April 30, 2003
Missing... presumed at random: cost-analysis of incomplete dataAndrew Briggs, Taane Clark, Jane Wolstenholme, et al.
BMC Health Services Research|July 17, 2019
Estimating the cost-effectiveness of salt reformulation and increasing access to leisure centres in England, with PRIMEtime CE model validation using the AdViSHE toolAdam D M Briggs, Jane Wolstenholme, Peter Scarborough
Plos One|May 26, 2018
Estimating comparable English healthcare costs for multiple diseases and unrelated future costs for use in health and public health economic modellingAdam D M Briggs, Peter Scarborough, Jane Wolstenholme
BMJ Open|June 22, 2022
Estimating BMI distributions by age and sex for local authorities in England: a small area estimation studyBen Amies-Cull, Jane Wolstenholme, Linda Cobiac, et al.
Population Health Metrics|May 7, 2016
Choosing an epidemiological model structure for the economic evaluation of non-communicable disease public health interventionsAdam D M Briggs, Jane Wolstenholme, Tony Blakely, et al.
Health Services Management Research|November 1, 2017
Translational health economics: The key to accountable adoption of in vitro diagnostic technologiesChristopher P Price, Jane Wolstenholme, Patrick McGinley, et al.
Pageof 6